15 completed, 6 terminated, 2 unknown, 1 recruiting. 16 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 11, Terminated 3, Recruiting 1, Unknown 1 |
| Phase 2 | 14 | Completed 6, Terminated 4, Unknown 2, Recruiting 1, Withdrawn 1 |
Follow Depsipeptides: new trials by email Literature Review of Depsipeptides trials Research Report on Depsipeptides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Parsaclisib, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Walter Hanel | 5 | 2021-09-01 | 2025-01-17 |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma Laboratory Biomarker Analysis, Romidepsin, Venetoclax - Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 12 | 2018-08-21 | 2023-10-19 |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Durvalumab, Pralatrexate, Romidepsin - Lymphoma, T-Cell | Phase 1 / Phase 2 | Recruiting | University of Virginia | 148 | 2018-05-30 | 2022-03-31 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Romidepsin, Busulfan, Fludarabine - Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 23 | 2017-12-08 | 2025-09-19 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 38 | 2017-11-14 | 2026-10-28 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer Romidepsin, Abraxane - HER2-negative Breast Cancer, Inflammatory Breast Cancer | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 9 | 2014-04-01 | 2025-05-16 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Alisertib, Laboratory Biomarker Analysis, Romidepsin - MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2013-07-17 | 2019-01-28 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 22 | 2012-10-29 | 2018-09-19 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
| Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Bortezomib, Romidepsin - Leukemia, Lymphoma | Phase 1 | Completed | Virginia Commonwealth University | 18 | 2010-04-26 | 2018-04-23 |
| Trial of Romidepsin and Bortezomib for Multiple Myeloma Bortezomib, Romidepsin - Multiple Myeloma | Phase 2 | Terminated | Celgene | 32 | 2008-09-01 | 2019-11-25 |
| A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma Romidepsin - Peripheral T-cell Lymphoma | Phase 2 | Completed | Celgene | 131 | 2007-06-19 | 2020-02-11 |
| A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma depsipeptide, bortezomib, dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Peter MacCallum Cancer Centre, Australia | 40 | 2006-11-01 | 2011-08-12 |
| A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors Romidepsin, Gemcitabine - Pancreatic Cancer | Phase 1 | Completed | Celgene | 36 | 2006-07-01 | 2019-10-30 |
| FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Depsipeptide - Malignant Melanoma, Melanoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 4 | 2005-10-04 | 2023-06-28 |
| FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer depsipeptide - Ovarian Cancer | Phase 2 | Withdrawn | University of Chicago | 2005-05-01 | 2013-09-05 | |
| FR901228 in Treating Patients With Recurrent High-Grade Gliomas depsipeptide - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 50 | 2005-01-01 | 2017-01-02 |
| A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) romidepsin (depsipeptide, FK228) - Cutaneous T-cell Lymphoma | Phase 2 | Completed | Celgene | 102 | 2005-01-01 | 2019-10-30 |
| Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum Depsipeptide, Flavopiridol (alvocidib) - Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | National Cancer Institute (NCI) | 23 | 2004-10-25 | 2019-12-12 |
Showing 20 of 25. Sign in to see all of them.
Lymphoma, T-Cell (8) · Lymphoma, T-Cell, Cutaneous (6) · Lymphoma, Large-Cell, Anaplastic (5) · Lymphoma, T-Cell, Peripheral (4) · Breast Neoplasms (3) · Immunoblastic Lymphadenopathy (3) · Lymphoma (3) · Mycosis Fungoides (3) · Carcinoma, Non-Small-Cell Lung (2) · Hodgkin Disease (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lung Neoplasms (2) · Lymphoma, B-Cell, Marginal Zone (2) · Melanoma (2) · Mesothelioma, Malignant (2)
National Cancer Institute (NCI) (6) · Celgene (5) · M.D. Anderson Cancer Center (2) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1) · Mayo Clinic (1) · Ohio State University Comprehensive Cancer Center (1) · Peter MacCallum Cancer Centre, Australia (1) · Royal Marsden NHS Foundation Trust (1) · SWOG Cancer Research Network (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Chicago (1) · University of Virginia (1) · Virginia Commonwealth University (1) · Walter Hanel (1)
United States (20) · Australia (2) · France (2) · Germany (2) · Poland (2) · United Kingdom (2) · Canada (1) · Czechia (1) · Russia (1) · Spain (1) · Sweden (1) · Ukraine (1)
David S Schrump, M.D. (2) · Amy Kimball, MD, PhD (1) · Beata Holkova, MD (1) · Daniel P. Petrylak, MD (1) · David H. Lawson, MD (1) · Dr Johann De Bono (1) · Enrica Marchi, M.D., PhD (1) · Gini Fleming, MD (1) · Grzegorz S. Nowakowski, M.D. (1) · Howard A. Burris, M.D. (1) · Howard Fine, MD (1) · Hun Lee (1) · Jasmine M Zain (1) · Jean Nichols, Ph.D. (1) · Jonathan Brammer, MD (1)
PMID 20697094, PMID 21377994, PMID 21911830, PMID 22271479, PMID 22536933, PMID 24456586, PMID 25279222, PMID 25605745, PMID 26965915, PMID 28103725, PMID 29622656, PMID 39863139
P30CA016672 (2), P30CA016059 (1), P30CA033572 (1), R21CA137823 (1), U01CA062399 (1), U01CA062461 (1), U01CA062505 (1), U01CA069912 (1), U01CA070095 (1), U01CA132123 (1), U10CA021115 (1), U10CA032102 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186688 (1)